AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 5/6 · 19/10/2026
Moat—
Insufficient evidence for every rubric criterion; no category score is inferred.
structural advantage · — · Scientific breadth, production infrastructure and specific share gains establish differentiation, but do not establish a durable structural barrier across the business. The uncertain verdict leaves this criterion ungraded.
durability · — · Established capabilities could persist, but the passages do not demonstrate the durability of competitive protection. Alternative-testing initiatives create a concrete potential source of erosion.
customer dependency · — · Contract conversion and Apollo adoption demonstrate activity, while customer losses and termination provisions limit conclusions about dependency. Switching friction is not established.
erosion resilience · — · Microbial-testing gains and recovering DSA demand offset customer losses and cost pressure. These mixed outcomes cannot establish resilience of an otherwise unproven structural moat.
Pricing power38
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 2/4 · Safety Assessment realized price increases in 2023, and small research-model pricing increased in 2025. These observed outcomes support selective pricing ability, but missing price-volume detail and portfolio coverage prevent a stronger company-wide conclusion.
retention · 2/4 · Indirect evidence is mixed: contract liabilities converted to revenue, DSA backlog recovered modestly, microbial-testing demand grew and Apollo gained substantial usage. Year-end backlog declines and actual CDMO customer losses offset these positives. No renewal or retention rate is inferred.
margin resilience · 1/4 · Resilience remains fragile: second-quarter non-GAAP operating margin fell from 22.1% to 20.5% because of direct and corporate costs. Manufacturing improved and realized savings provide offsets, but first-half GAAP improvement largely reflected asset sales, amortization and prior legal costs rather than demonstrated pricing protection.
contractual freedom · 1/4 · Disclosed fixed-price contracts constrain repricing, and clients or regulators can terminate or delay projects. These contractual limitations support a low grade; associated risk language does not establish realized price cuts or universal contract terms.
Predictability87
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 50.00
- Revenue growth volatility (pp)
- 5.61
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 2.78
Financial strength25
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 55.33
- netDebtEbitGrade
- 0.00
- interestCoverageGrade
- 0.00
- currentRatioGrade
- 43.33
- Debt / FCF (x)
- 4.13
- Net debt / operating income (x)
- 76.54
- Interest coverage (x)
- 0.24
- Current ratio (x)
- 1.29
Capital allocation55
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 5.07
- 3-year average dilution (%)
- -0.81
- 3-year average SBC / revenue (%)
- 1.75
- cashConversionGrade
- 0.00
Management56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · 2025 operating cash generation, lower capital spending and debt repayments support discipline. Customer-related impairments and substantial divestiture losses show setbacks. First-half 2026 acquisition spending and repurchases accompanied lower operating cash flow and higher debt; returns on recent acquisitions remain unproven.
incentive alignment · 2/4 · Existing three-year PSUs, relative shareholder-return conditions, approved performance-weighted 2025 awards and ownership guidelines support alignment. First-year non-GAAP EPS materially determines PSU outcomes, and the 139% bonus payout despite customer losses and impairments makes the overall evidence mixed. Actual ownership compliance is unavailable.
execution · 2/4 · Reported realized savings, microbial-testing share gains, digital adoption, supply-chain integration and improving regulated-testing volume demonstrate achievements. Customer losses, recurring restructuring and divestiture losses offset them. Execution is assessed from disclosed operating outcomes; the year-end savings objective and 2030 targets remain prospective.
governance · 3/4 · A majority-independent board, independent principal committees and documented audit oversight support strong governance structures and activity. Exceptional effectiveness is not established. DOJ investigations closed in 2025; unresolved derivative allegations are not findings of misconduct.
Evidence
We continue to maintain our position as a global leader in the production and sale of the most widely used research models, including over 140 different stocks and strains of purpose-bred rodents.
Business / RMS research-model portfolio and issuer leadership claim · Filed 18/02/2026
We maintain multiple production centers, including barrier rooms and isolator facilities, on three continents (North America, Europe, and Asia).
Business / production infrastructure · Filed 18/02/2026
We have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development.
Business / scientific capabilities and service portfolio · Filed 18/02/2026
Within the Manufacturing segment, the Microbial Solutions business saw robust growth benefitting from strong demand across the comprehensive manufacturing quality-control testing portfolio, including Accugenix® microbial identification services, led by increased AxxessTM instrument placements; share gains for our Endosafe® endotoxin testing platform; and higher sales of Celsis® microbial detection products.
MD&A / Microbial Solutions growth and reported share gains · Filed 18/02/2026
In addition, small, specialized entities considering entering the industries will continue to find lower barriers to entry, and private equity firms may determine that there are opportunities to acquire and consolidate these companies, thus further increasing possible competition.
Risk Factors / lower barriers for specialized entrants · Filed 18/02/2026
For example, in April 2025, the FDA announced its intention to reduce animal testing in preclinical safety studies with NAMs, such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays; in October 2025, the FDA announced its intention to streamline the approval process for biosimilar drug development and indicated further announcements related to reducing animal testing requirements may be forthcoming; and in November 2025, the U.K.
Risk Factors / FDA initiatives concerning alternative testing · Filed 18/02/2026
The decrease in operating income and operating income margin for fiscal year 2025 was primarily due to the intangible asset impairment charges within our Manufacturing and RMS businesses, the acceleration of amortization expense recognized as a result of a decrease in the remaining useful life of certain CDMO client relationships due to a loss of key customers, and the revenue impacts described above; partially offset by a decrease in charges related to goodwill impairments within our Manufacturing business, lower severance costs and the absence of an inventory charge incurred in connection with the investigations by the U.S.
MD&A / impairments and actual loss of key CDMO customers · Filed 18/02/2026
•To refine and further strengthen its portfolio, the Company completed the divestitures of certain European Discovery Services sites as well as the CDMO and Cell Solutions businesses in May 2026.
Second-quarter 2026 highlights / completed divestitures · Filed 05/08/2026
The Safety Assessment revenue growth rate moderated due to our clients’ budgetary spending constraints but continued to report a solid growth rate for the fiscal year due to a combination of price increases and study volume.
MD&A / 2023 realized Safety Assessment pricing and volume · Filed 14/02/2024
Revenue for RMS increased in fiscal year 2025 due largely to higher revenue from large research models and increased pricing for small research models.
MD&A / 2025 research-model revenue and realized pricing · Filed 18/02/2026
Backlog
Our backlog for our RMS, DSA and Manufacturing reportable segments was approximately $640 million, $1.9 billion and $123 million, respectively, as of December 27, 2025, as compared to $685 million, $2.0 billion and $103 million, respectively, as of December 28, 2024.
Business / year-end 2025 segment backlog comparison · Filed 18/02/2026
As we continue to navigate these challenges in the current macroeconomic environment, DSA backlog increased slightly to $2.0 billion as of June 27, 2026 from $1.9 billion as of December 27, 2025.
MD&A / June 2026 DSA backlog · Filed 05/08/2026
Approximately 70% of contract liabilities as of December 27, 2025, which was $256 million, were recognized as revenue during the six months ended June 27, 2026.
Revenue recognition / actual conversion of contract liabilities · Filed 05/08/2026
Fourth, studies or projects may be terminated or delayed at any time by the client or regulatory authorities for a number of reasons, including the failure of a drug to satisfy safety and efficacy requirements, or a sponsor making a strategic decision that a study or service is no longer necessary.
Business / client and regulatory termination or delay provisions · Filed 18/02/2026
Competition and fixed price contracts may limit our ability to maintain existing operating margins.
Risk Factors / competition and fixed-price contracts · Filed 18/02/2026
The increases in operating income and operating income as a percentage of revenue for the three and six months ended June 27, 2026 were primarily driven by the gain on sale of certain assets at our Wilmington, Massachusetts site in the first quarter of 2026, lower accelerated amortization expense, and certain third-party legal costs incurred in fiscal year 2025; partially offset by the decrease in revenue described above and higher acquisition, integration and divestiture costs, when compared to the corresponding period in 2025.
MD&A / drivers of first-half operating-income improvement · Filed 05/08/2026
On a non-GAAP basis, the second-quarter operating margin decreased to 20.5% from 22.1% in the second quarter of 2025, primarily as a result of higher study-related direct costs in the DSA segment and higher unallocated corporate costs.
Second-quarter results / underlying margin decline and cost drivers · Filed 05/08/2026
SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1)
(in thousands, except percentages)
Three Months Ended
Six Months Ended
June 27, 2026
June 28, 2025
June 27, 2026
Non-GAAP operating income as a % of revenue
25.6
%
27.4
%
23.3
%
25.7
%
Depreciation and amortization
$
41,633
$
42,575
$
81,547
$
84,659
Capital expenditures
$
20,433
$
18,500
$
57,942
$
53,021
Manufacturing Solutions
Revenue
$
188,096
$
200,835
$
378,636
$
379,321
Operating income
65,606
12,061
112,445
3,441
Operating income as a % of revenue
34.9
%
6.0
%
29.7
%
0.9
%
Add back:
Amortization related to acquisitions (2)
2,061
46,333
4,006
92,410
Acquisition, integration, and divestiture-related adjustments (3)
2,764
—
2,764
—
Severance
326
(383)
(542)
1,821
Asset impairment
251
6,157
251
6,358
Cost savings and efficiency initiatives (4)
140
1,670
1,511
2,976
Total non-GAAP adjustments to operating income
$
5,542
$
53,777
$
7,990
$
103,565
Operating income, excluding non-GAAP adjustments
$
71,148
$
65,838
$
120,435
$
107,006
Non-GAAP operating income as a % of revenue
37.8
%
32.8
%
31.8
%
28.2
%
Depreciation and amortization
$
7,389
$
55,343
$
15,788
$
109,966
Capital expenditures
$
5,634
$
11,161
$
11,908
$
28,440
Unallocated Corporate Overhead
$
(106,394)
$
(70,494)
$
(186,984)
$
(124,762)
Add back:
Acquisition, integration, and divestiture-related adjustments (3)
18,173
2,161
34,762
2,891
Severance
1,000
574
4,671
1,576
Asset impairment
543
184
543
184
Cost savings and efficiency initiatives (4)
14,612
503
11,697
669
Third-party legal and advisory costs (5)
—
Segment reconciliation / Manufacturing margin improvement · Filed 05/08/2026
Collectively, these actions are expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026, of which more than $175 million benefitted fiscal year 2025.
MD&A / reported 2025 savings and prospective 2026 target · Filed 05/08/2026
We incurred restructuring charges of $23.1 million and $54.6 million during the three and six months ended June 27, 2026, and $99.8 million and $107.0 million during the fiscal years 2025 and 2024, respectively.
MD&A / actual restructuring charges · Filed 05/08/2026
Trade receivables and contract assets, net
35,737
21,612
(33,434)
Inventories
(48,777)
16,804
(62,301)
Accounts payable
2,869
(14,271)
(20,427)
Accrued compensation
79,308
(27,604)
12,447
Deferred revenue
(38,139)
18,541
(21,743)
Customer contract deposits
14,652
6,584
(15,564)
Other assets and liabilities, net
(31,569)
(51,995)
38,642
Net cash provided by operating activities
737,646
734,577
683,898
Cash flows relating to investing activities
Capital expenditures
(219,152)
(232,967)
(318,528)
Purchases of investments and contributions to venture capital investments
(20,076)
(52,876)
(54,215)
Acquisition of businesses and assets, net of cash acquired
(5,479)
(194,785)
Proceeds from sale of investments
9,102
41,687
6,667
Proceeds from sale of businesses, net
17,441
Other, net
3,364
4,549
(2,294)
Net cash used in investing activities
(209,321)
(245,086)
(563,155)
Cash flows relating to financing activities
Cash flow statement / operating cash generation and capital expenditures · Filed 18/02/2026
For fiscal year 2025, net cash used in financing activities was primarily driven by the following activity: •Net repayments of $111.2 million towards our Credit Facility •Treasury stock purchases of $350.0 million associated with our stock repurchase program and $10.1 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements •Payment of $21.8 million associated with contingent consideration related to the acquisition of Noveprim •Payment of $19.1 million for the remaining 8% equity interest in Vital River 56 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Liquidity / actual debt repayments and capital distributions · Filed 18/02/2026
The decrease of $94.1 million for the six months ended June 27, 2026 was due principally to the CDMO and Cell Solutions Divestiture loss of $181.7 million recognized in the first half of 2026, partially offset by the increase in operating income described above, compared to the corresponding period in 2025.
MD&A / first-half 2026 divestiture loss · Filed 05/08/2026
During the six months ended June 27, 2026, our cash flows from operations were $220.8 million compared with $376.3 million for the same period in 2025.
Liquidity / first-half operating cash flow comparison · Filed 05/08/2026
The following table presents our net cash used in investing activities: Six Months Ended June 27, 2026 June 28, 2025 (in thousands) Acquisition of businesses and assets, net of cash acquired $ (467,254) $ — Capital expenditures (87,013) (94,622) Investments, net (746) (5,984) Proceeds from sale of businesses and assets, net 176,563 17,441 Other, net (1,298) 347 Net cash used in investing activities $ (379,748) $ (82,818) Investing activities primarily consist of cash used to fund capital expenditures to support the growth of our business, purchases and sales of investments related to our venture capital and strategic equity investment portfolios, and asset and business acquisitions, periodically offset by cash from divestitures.
Liquidity / acquisition spending and capital expenditures · Filed 05/08/2026
During the six months ended June 27, 2026, we repurchased 1.7 million shares of common stock for $300.0 million under the stock repurchase program.
Liquidity / completed first-half share repurchases · Filed 05/08/2026
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except per share amounts) June 27, 2026 December 27, 2025 Assets Current assets: Cash and cash equivalents $ 192,025 $ 213,770 Trade receivables and contract assets, net of allowances for credit losses of $8,715 and $10,463, respectively 711,755 708,856 Inventories 346,260 299,103 Prepaid assets 100,409 96,108 Other current assets 178,657 129,212 Total current assets 1,529,106 1,447,049 Property, plant and equipment, net 1,494,914 1,655,219 Venture capital and strategic equity investments 206,470 206,972 Operating lease right-of-use assets, net 330,247 361,415 Goodwill 3,076,851 2,764,253 Intangible assets, net 253,174 339,995 Deferred tax assets 53,827 67,334 Other assets 587,556 293,185 Total assets $ 7,532,145 $ 7,135,422 Liabilities, Redeemable Noncontrolling Interests and Equity Current liabilities: Accounts payable $ 140,983 $ 148,800 Accrued compensation 187,835 268,854 Deferred revenue 203,035 210,418 Accrued liabilities 380,101 270,085 Other current liabilities 222,792 222,158 Total current liabilities 1,134,746 1,120,315 Long-term debt, net and finance leases 2,619,985 2,136,360 Operating lease right-of-use liabilities 407,708 434,048 Deferred tax liabilities 78,668 95,203 Other long-term liabilities 402,511 138,302 Total liabilities 4,643,618 3,924,228 Commitments and contingencies (Notes 2, 12, 14, and 16) Redeemable noncontrolling interests 42,537 41,263 Equity: Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding — — Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025 496 492 Additional paid-in capital 1,986,023 1,947,301 Retained earnings 1,372,295 1,388,620 Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively (323,189) — Accumulated other comprehensive loss (195,989) (171,783) Total Charles River Laboratories International, Inc.
Balance sheets / debt and finance leases comparison · Filed 05/08/2026
Performance Share Units (PSUs), which vest on a “cliff basis” after three years, if service and performance requirements are met and which are paid out in shares based upon two separate performance metrics: (1) first fiscal year non-GAAP earnings per share (EPS) and (2) three-year rTSR.
Compensation / existing PSU service and performance conditions · Filed 31/03/2026
The Committee approved Long-Term Equity Incentive Awards for executives for fiscal 2025 to be delivered in the form of 60% PSUs and 40% RSUs and for the CEO to receive 80% PSUs and 20% RSUs.
Compensation / approved fiscal 2025 equity award mix · Filed 31/03/2026
Under these guidelines, members of our senior management are required to maintain an ownership position, expressed as a multiple of salary, as follows: CEO 6 times base salary Executive Vice President 3 times base salary Senior Vice President 2 times base salary Vice President 1 time base salary Members of senior management have four years from the time they attain the executive level listed above to comply with the ownership requirements.
Compensation / salary-multiple ownership guidelines · Filed 31/03/2026
For fiscal year 2025, we exceeded our Revenue and Operating Income goals, which resulted in a bonus payout of 139% of target in 2025.
Compensation / actual 2025 bonus outcome · Filed 31/03/2026
Nine of the eleven members of our Board of Directors are independent and have no significant financial, business or personal ties to us or management.
Corporate governance / board independence · Filed 18/02/2026
Our Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee of our Board of Directors are each composed entirely of independent directors.
Corporate governance / independent principal committees · Filed 18/02/2026
Met with our management, internal auditors, and PricewaterhouseCoopers LLP, separately and together, to discuss our financial reporting process and internal control over financial reporting, and discussed with the auditors the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and Securities and Exchange Commission.
Audit Committee report / actual oversight activities · Filed 31/03/2026
Furthermore, in August 2025 the Company was advised by the DOJ that both the grand jury investigation and the parallel civil investigation had been closed.
Litigation / closure of DOJ investigations · Filed 18/02/2026
District Court of Delaware asserting similar derivative claims on the Company’s behalf against members of the Company’s current and former Board of Directors and the same current/former officers based on similar allegations of purportedly misleading disclosures and non-compliance with legal rules and ethics standards in respect of the importation of non-human primates, as well as insider-trading claims against certain of the defendants.
Litigation / unresolved derivative allegations · Filed 05/08/2026
Apollo™ now serves more than 18,000 client users through its scientific decision-support and e-commerce capabilities and was recently expanded to support Manufacturing Solutions’ clients.
Investor Day / reported Apollo client-user adoption · Filed 24/09/2026
Organic revenue increased by 0.2%, driven primarily by higher study volume for regulated safety assessment services.
DSA results / realized regulated safety-assessment volume growth · Filed 05/08/2026
The financial targets are not projections and do not constitute financial guidance; they are subject to significant uncertainties and contingencies and are based upon management's current assumptions, which are subject to change.
Investor Day / prospective status of long-term financial targets · Filed 24/09/2026
This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers.
Acquisitions / actual NHP supply-chain integration · Filed 05/08/2026
government announced a roadmap to phasing out animal testing in favor of alternative methods.
Risk Factors / UK alternative-testing roadmap · Filed 18/02/2026
However, we may not be able to develop new products, inputs or processes effectively or in a timely manner to replace any lost sales.
Risk Factors / uncertainty of replacement-product development · Filed 18/02/2026
